RenovoRx, Inc.
RNXT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -37% | 114.2% | 358.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 80.1% | 64% | 52.3% | 100% |
| R&D Expenses | $2 | $1 | $2 | $2 |
| G&A Expenses | $0 | $2 | $2 | $1 |
| SG&A Expenses | $2 | $2 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $3 | $3 | $3 |
| Operating Income | -$3 | -$3 | -$3 | -$3 |
| % Margin | -1,203% | -634.6% | -1,578.7% | -6,120.9% |
| Other Income/Exp. Net | $0 | -$0 | $1 | -$0 |
| Pre-Tax Income | -$3 | -$3 | -$2 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$3 | -$2 | -$3 |
| % Margin | -1,094.7% | -686% | -1,228.4% | -6,693% |
| EPS | -0.08 | -0.079 | -0.077 | -0.13 |
| % Growth | -1% | -2.7% | 40.7% | – |
| EPS Diluted | -0.08 | -0.079 | -0.077 | -0.13 |
| Weighted Avg Shares Out | 37 | 37 | 31 | 22 |
| Weighted Avg Shares Out Dil | 37 | 37 | 31 | 22 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $3 |
| EBITDA | -$3 | -$3 | -$2 | $0 |
| % Margin | -1,094.4% | -634.4% | -1,227.9% | 0% |